Trial Profile
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 22 Mar 2024 Planned End Date changed from 30 Jun 2023 to 21 Mar 2025.
- 15 Jun 2023 Results assessing safety and efficacy of the HDACi entinostat + anti-PD1 antibody pembrolizumab in MDS oroligoblastic AML after HMA failure presented at the 28th Congress of the European Haematology Association
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition